Dasatinib is an inhibitor of multiple tyrosine kinases. It is marketed as Sprycel for the treatment of chronic myeloid leukemia (CML). It is also indicated for the treatment of adults with Philadelphia chromosome- positive acute lymphoblastic leukemia.